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ment levels (urine Ca/Cr in WT, 0.11  0.01 to 0.76  0.05,Cyclosporine A-induced hypercalciuria in calbindin-D28k knock-
P  0.01; in KO, 0.39  0.05 to 0.79  0.06; P  0.01).out and wild-type mice.
Conclusion. Calbindin-D28k KO mice have diet-dependentBackground. It is known that cyclosporine A (CsA) treat-
hypercalciuria and a lower bone turnover rate. CsA treatmentment induces high bone-turnover osteopenia and hypercal-
suppresses the expression of calbindin-D28k in mice, but hasciuria. It has been proposed that down-regulation of renal
no effects on ECaC and 1G gene expression at the mRNAcalbindin-D28k by CsA results in renal calcium wasting. We
level. The pathogenesis of CsA-induced hypercalciuria involvesinvestigated the role of the kidney and bone in CsA-induced
both down-regulation of calbindin-D28k with subsequent im-hypercalciuria in calbindin-D28k knockout (KO) and wild-type
paired renal calcium reabsorption and CsA-induced high turn-(WT) mice.
over bone disease. Additionally, our results suggest that mecha-Methods. Two sets of experiments were performed. In ex-
nism(s) independent of calbindin-D28k within the kidney alsoperiment 1, KO and WT mice were treated with CsA 20 mg/kg/
may contribute to the CsA-induced calcium leak.day intraperitoneally (IP) for 7 days. In experiment 2, to elimi-
nate the CsA effect on bone resorption, pamidronate (APD)
2.5 mg/kg IP was given every 4 days with the first dose given
4 days prior to the 7-day course of CsA. Serum levels of creati-
Cyclosporine A (CsA), a well-established immunosup-nine, calcium, and osteocalcin, as well as renal calcium excre-
pressive agent, has been widely used in the managementtion were measured to assess CsA’s effects on calcium homeo-
stasis. Effects of CsA on the expression of calbindin-D28k, and of organ transplantation and autoimmune diseases. The
two calcium channels in the apical membrane of the distal main action of this agent is to inhibit T-cell function by
tubule, epithelial calcium channel (ECaC) and 1G-subunit of binding to intracellular cyclophilin and subsequent block-a voltage-dependent Ca channel (1G), in the kidney were
age of calcineurin and IL-2 gene transcription [1]. It hasexamined by semiquantitative reverse transcription polymer-
been recognized that CsA exhibits several side effectsase chain reaction (RT-PCR).
Results. KO mice had a threefold increase in renal calcium including nephrotoxicity. Prolonged use of CsA may re-
excretion when compared with WT mice at the baseline. This sult in chronic renal failure with tubulointerstitial fibrosis
difference disappeared when calcium load was reduced by over-
and microcalcification within or adjacent to tubular cellsnight fasting. After the CsA treatment, both WT and KO mice
[2]. In addition, CsA is known to cause renal tubular dys-had a significant increase of renal calcium excretion (urine
Ca/Cr ratio in WT, 0.11  0.01 to 1.29  0.17; in KO, 0.39  function such as renal magnesium wasting, distal tubular
0.04 to 1.18  0.13; both P  0.01). CsA treatment decreased acidosis and impaired renal potassium excretion [3, 4].
renal calbindin-D28k mRNA by 61%, but did not affect the More recently, it has been reported that CsA treat-
expression of ECaC and 1G. Baseline serum osteocalcin level
ment causes hypercalciuria in animal studies. CsA treat-of KO mice was significantly lower than that of WT mice. After
ment in rats at the dosage of 15 to 50 mg/kg for 7 to 14CsA treatment, both groups had a 50% increase in the serum
osteocalcin level, indicating increased bone turnover. When days increased urine calcium excretion by 60 to 330%
mice were treated with both CsA and APD, the increase in [5–7]. It has been proposed that down-regulation of renal
serum osteocalcin level was prevented, and renal calcium excre- calbindin-D28k may be the pathogenesis of CsA-inducedtion was significantly lower than that in mice treated with CsA
hypercalciuria [6, 7]. Calbindin-D28k is an intracellularalone. However, there was still a significant increase in the
calcium binding protein, which plays an important roleurine Ca/Cr ratio in WT and KO mice compared with pretreat-
in calcium transport [8–11]. This protein is regulated by
vitamin D and exclusively expressed in the distal tubuleKey words: calcium channels, bisphosphonate, knockout mice, immu-
where it colocalizes with calcium channels including epi-nosuppressant, organ transplantation, bone turnover, urinary calcium,
osteopenia. thelial calcium channel (ECaC) and 1G-subunit of a
voltage-dependent Ca channel (1G) [12–14]. Function-Received for publication January 28, 2002
ally, it has been shown that calbindin-D28k increasesand in revised form May 22, 2002
Accepted for publication July 15, 2002 calcium uptake in the distal tubule in vitro [11]. Steiner
et al first reported that CsA decreases calbindin-D28k 2002 by the International Society of Nephrology
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in rat kidney by two-dimensional gel electrophoresis [15]. reduce bone resorption in rats [20]. This protocol was
adopted from what described by Sass et al [21], withThey and others subsequently demonstrated that this de-
crease is due to decreased transcription of calbindin-D28k minor modifications. CsA was given daily for seven days
as in Experiment 1. Blood and urine samples were col-and is linked to CsA-induced hypercalciuria [6, 7, 16].
Recently, calbindin-D28k knockout (KO) mice have lected before and at the end of CsA treatment.
been generated by targeted gene disruption [17]. These
Blood, urine collection and analysesmice have impaired motor coordination probably due
to functional deficits in cerebellar pathways. To further Tail vein blood was collected in heparinized tubes and
centrifuged immediately to separate serum from blood.examine the role of calbindin-D28k on CsA-induced
hypercalciuria, we compared the effects of CsA on cal- Urine samples were collected in individualized metabolic
cages (Nalgene, Rochester, NY, USA). To evaluate thecium metabolism in calbindin-D28k KO and wild-type
(WT) mice in this study. effect of food intake, an overnight fasting urine sample
was collected for each mouse. Measurements of creatinine
and calcium levels in serum and urine were performed us-
METHODS
ing colorimetric assay kits based on color reactions between
Animals creatinine and picrate, and calcium and cresolphthalein,
respectively (Sigma, St. Louis, MO, USA). Serum osteo-Calbindin-D28k KO mice developed by Airaksinen
et al were purchased from the Jackson Laboratories (Bar calcin was determined by a radioimmunoassay method
using mouse osteocalcin immunoradiometric assay kitsHarbor, ME, USA), and maintained at the University
of Arizona animal facilities [17]. Mice C57BL6 were (Alpco Diagnostics, Windham, NH, USA).
chosen as a control because they are the strain from
RT-PCRwhich the null-mutant was generated originally [17]. All
mice used in this study were male, six to eight weeks old Since previous studies of CsA effects on calbindin-
D28k were all performed in rats [6, 7, 15, 16], we evalu-with a body weight of 25 to 32 g. All animals were allowed
free access to both food and drinking water except that ated calbindin-D28k expression in the mouse kidney
after CsA treatment. In addition, the effects of CsA onthey were fasted (food only) overnight once at the base-
line and once after CsA treatment prior to urine collec- the expression of the two newly identified calcium chan-
nels ECaC and 1G [12–14], which are expressed exclu-tion. The feeding diet is Harlan Teklad LM-485 diet
(Madison, WI, USA) containing 1% calcium. The pres- sively in the distal tubule, were evaluated also. Semi-
quantitative RT-PCR was performed using 2 g RNAent study was performed in accordance with the guide-
lines and practice of Arizona animal care committee. samples isolated from the whole kidney of WT and KO
mice with and without CsA treatment. RT was performed
Study protocols using AMV reverse transcriptase (AMV, Roche, IN,
USA). The primers used for each PCR product includingExperiment 1. Twelve KO and 12 WT mice were
treated with CsA (Novartis, Summit, NJ, USA) via intra- the internal standard, -actin, are listed in Table 1. To
make sure that RT-PCR products were quantitated atperitoneal (IP) injection (20 mg/kg/day) for seven days.
The dosage and duration have been shown previously the exponential phase, the exponential range was deter-
mined experimentally by quantitating the RT-PCR prod-to cause hypercalciuria without renal insufficiency [5–7].
Blood and urine samples were collected before and at ucts at different PCR cycles. It was determined that the
RT-PCR products were measurable and were still at thethe end of treatment. Eight mice were killed in each group
at the end of treatment and kidneys were harvested for exponential phase at cycle 20 in all genes tested (data
not shown). Subsequent RT-PCR quantitations werereverse transcription-polymerase chain reaction (RT-
PCR) and Western blot analyses. The other four mice conducted at the end of 20 PCR cycles. PCR conditions
were MgCl2 1.5 mmol/L and an annealing temperaturewere allowed to recover and blood and urine samples
were collected seven days after discontinuing CsA. 58C. A trace amount of [P32]-dATP (1Ci) was added to
each PCR reaction to increase the sensitivity of productExperiment 2. It is known that CsA administration in
rats produces a high remodeling bone loss. The enhanced detection as described previously [22]. PCR products
were then electrophoresed in 1 Gene Amp Detectionbone resorption may increase calcium filtration load and
subsequently renal calcium excretion [18, 19]. To mini- Gel (Perkin-Elmer, Norwalk, CT, USA). The gel was
dried and subjected to quantification analysis using In-mize the effects of CsA on bone resorption, in the second
set of experiments, eight mice in each group were treated stant Imager (Packard, Downers Grove, IL, USA).
with 3-amino-1-1-hydroxypropylidene (APD; Pamidro-
Western blot analysisnate; Novartis), 2.5 mg/kg IP, every four days starting
four days prior to the first CsA treatment. This dosage Kidney tissue was homogenized in protein lysis buffer
[phosphate-buffered saline (PBS) pH 7.2, containing 0.1of APD has been shown to increase bone density and
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Table 1. Primers used for polymerase chain reaction (PCR) was significantly lower than that in WT mice (27% de-
crease, P  0.05).Gene Oligonucleotide sequence
Calbindin-D28k
Experiment 1: CsA treatmentForward 5-CAGAATCCCACCTGCAGTC-3
Reverse 5-GTAGTAACCTGGCCATCTCTG-3 The effects of CsA on calcium metabolism in WT and
Epithelial calcium channel
KO mice are shown in Table 2. CsA did not affect body(ECaC)
Forward 5-CCTCAAGTTCCGTGATGCC-3 weight, serum creatinine (SCr) and Ca levels; however,
Reverse 5-CATTAGCCAGCAGAAGCG-3 after CsA treatment for seven days, a remarkable in-
1G subunit of
crease of renal calcium excretion was found in both WTvoltage-gated calcium
channel (1G) and KO mice (Urine Ca/Cr ratio in WT, 0.11  0.01 to
Forward 5-CCTCAACTGTATCACCATCG-3 1.29  0.17; in KO, 0.39  0.04 to 1.18  0.13; both P 
Reverse 5-GACACACGAAGAACTTCCC-3
0.01). The degree of hypercalciuria induced by CsA was-actin
Forward 5-ACCACACCTTCTACA-3 not different between the WT and KO mice. This in-
Reverse 5-GGCACAGTGGGTGACC-3 crease was attenuated by overnight fasting; the urine
Ca/Cr ratio was reduced by 40% and 25%, in WT and
KO mice, respectively (both P 0.01 vs. nonfasting group),
but the ratio was still significantly higher than the pre-mmol/L dithiothreitol (DTT), and protease inhibitors in-
cluding 1 mmol/L phenylmethylsulfonyl fluoride (PMSF), treatment levels. Serum osteocalcin measurement showed
a 50% increase after CsA treatment both in WT (P 1 mmol/L ethylenediaminetetraacetic acid (EDTA), 5 g/mL
leupeptin, and 5 g/mL aprotinin; all purchased from 0.01 vs. pretreatment) and KO mice (P  0.05). The
CsA-induced hypercalciuria was reversed one week afterSigma]. Samples were then resolved by 10% sodium do-
decyl sulfate-polyacrylamide gel electrophoresis (SDS- withdrawing CsA. The urine Ca/Cr ratio was 0.06  0.01
and 0.11  0.02, respectively, in WT and KO mice withPAGE) and transferred to nitrocellulose membranes.
After blocking with 2% non-fat milk, the membrane was overnight fasting (N	 4, both P
 0.05 vs. pretreatment).
incubated with mouse monoclonal anti-chicken calbin-
Experiment 2: CsA and APD treatmentdin-D28k antibodies (1:4000; Sigma) for 1.5 hours. Fur-
ther washing in 0.5% blocking milk was performed and In the second set of experiments, APD was given four
days prior to the CsA treatment and urine samples weremembrane was incubated with goat anti-mouse antibody
conjugated with horseradish peroxidase (1:30,000; Sigma) collected 24 hours prior to CsA treatment. The urine
Ca/Cr ratio was not affected by APD treatment alonefor 30 minutes. Signal emission was detected by chemilu-
minescence method using ECL PLUS reagent (Amer- in both WT and KO mice (nonfasting WT, 0.11  0,02
to 0.12  0.04; nonfasting KO, 0.39  0.05 to 0.31 sham Pharmacia, Piscataway, NJ, USA).
0.07; fasting WT, 0.11  0.02 to 0.09  0.02; fasting KO,
Statistics 0.13  0.03 to 0.13  0.04; all P 
 0.05 vs. pretreatment
levels). Subsequently, mice received daily injection ofAll data were presented as mean  SE. Comparisons
between pre-and post-treatment groups, as well as fast- CsA and two more injections of APD (4 days apart).
The results are shown in Table 3. Body weight, seruming and non-fasting groups, were assessed statistically by
the paired Student t test. An unpaired test was utilized creatinine and calcium were not affected by the treat-
ment. The addition of APD completely reversed the CsAfor statistical analysis between WT and KO mice. The
statistical analyses of multiple groups in RT-PCR and effects on the serum osteocalcin levels. The urine Ca/Cr
ratio was significantly lower than that with CsA treat-Western blot analysis were performed with the one-way
ANOVA using Bonferroni’s method for post-hoc analy- ment alone. The addition of APD reduced urine Ca/Cr
ratio by 41% and 32% in WT and KO mice, respectively,sis. Statistical significance was reported at the P  0.05
and P  0.01 levels. compared with the groups given CsA alone. However,
compared with untreated mice, both WT and KO mice
still had a significant increase in the urine Ca/Cr ratio
RESULTS
(WT, 0.11  0.01 to 0.76  0.05; KO, 0.39  0.05 to
Characterization of calbindin-D28k KO mice 0.79  0.06; both P  0.01). The urine Ca/Cr ratio was
further reduced after overnight fasting, but there wasThe baseline data of KO and WT mice are listed in
Table 2. There were no differences in body weight, and still significant calcium wasting when compared with pre-
treatment levels.serum creatinine and calcium levels between WT and
KO mice. Without fasting, the urine Ca/Cr ratio was
Cyclosporine effects on calbindin-D28k expressionthreefold higher in KO mice when compared with WT
mice (P 0.01). This difference was eliminated by over- To evaluate CsA effects on calbindin-D28k gene ex-
pression, calbindin-D28k mRNA was measured in thenight fasting. The serum osteocalcin level in KO mice
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Table 2. Effects of cyclosporine A on wild-type and calbindin-D28k knockout mice
Wild-type Calbindin-D28k knockout
Before After Before After
Body weight g 26.52.9 26.93.1 28.32.1 28.72.5
Serum Cr mg/dL 0.310.04 0.290.03 0.340.06 0.360.05
Serum Ca mg/dL 9.320.36 8.930.17 9.220.24 8.620.15
Urine Ca/Cr ratio
Non-fasting 0.110.01 1.290.17a 0.390.05b 1.180.13a
Fasting 0.110.02 0.780.11a,c 0.140.02c 0.890.11a,f
Serum osteocalcin ng/mL 15418 22620a 1147e 17115d
N 	 12.
a P  0.01 after vs. before treatment
b P  0.01 knockout vs. wild-type
c P  0.01 fasting vs. non-fasting
d P  0.05 after vs. before treatment
e P  0.05 knockout vs. wild-type
f P  0.05 fasting vs. non-fasting
Table 3. Effects of pamidronate and cyclosporine A on wild-type and calbindin-D28k knockout mice
Wild-type Calbindin-D28k knockout
Before After Before After
Body weight g 26.51.6 26.21.8 28.02.4 28.42.6
Serum Cr mg/dL 0.260.02 0.270.02 0.250.02 0.220.02
Serum Ca mg/dL 9.260.21 8.840.11 9.820.34 9.151.09
Urine Ca/Cr ratio
Non-fasting 0.110.02 0.760.05a 0.390.05b 0.790.06a
Fasting 0.110.02 0.340.05a,c 0.130.03c 0.410.05a,c
Serum osteocalcin ng/mL 16225 13214 11619d 7410
N 	 8.
a P  0.01 after vs. before treatment
b P  0.01 knockout vs. wild-type
c P  0.01 fasting vs. non-fasting
d P  0.05 knockout vs. wild-type
kidney by semiquantitative RT-PCR. Figure 1 shows els in both WT and KO mice (N 	 4 in each group. all
representative results of the RT-PCR analysis. In WT P 
 0.05).
mice, CsA treatment was associated with a significant
reduction in the calbindin-D28k/-actin ratio in the kid-
DISCUSSIONney (61% decrease, N 	 4, P  0.01 vs. pretreatment
The calbindin-D28k KO mouse is a very useful modellevels). As expected, samples from the KO mice did not
for studying calcium homeostasis. Previous studies [23]demonstrate any calbindin-D28k signal.
showed that KO mice fed a high calcium diet (1% Ca)Western blot analyses showed a similar change in cal-
had a two- to threefold increase in the urinary Ca/Crbindin-D28k protein levels. Figure 2 displays the protein
ratio compared with WT controls. There were no differ-expression of calbindin-D28k in untreated and CsA-
ences in serum PTH or 1,25 dihydroxyvitamin D3 levelstreated WT mice. After one week of CsA treatment,
between KO and WT mice when fed with a high calciumthere was a 52% decrease of calbindin-D28k protein
diet. Hypercalciuria was not observed in KO mice fed(N	 4, P 0.01 vs. pretreatment levels). The CsA effect
with a low calcium diet (0.02% Ca). Our studies confirmon calbindin-D28k protein expression was reversed after
that KO mice manifest significant renal calcium leak.withdrawal of CsA. Again, samples from the KO mice
These results demonstrate, to our knowledge for the firstdid not demonstrate any calbindin-D28k signal.
time, that the expression of ECaC and 1G, which are
Cyclosporine effects on expression of calcium channels both key apical calcium channels in the distal tubule, is
not affected by the absence of calbindin-D28k. In ourThe effects of CsA on the expression of ECaC and
study, KO mice had a threefold increase in urinary cal-1G in the kidney are shown in Figure 3. The abundance
cium excretion compared with the wild-type mice whenof ECaC and 1G mRNA in the kidney were not differ-
they were fed with a high calcium diet. This increase wasent between the WT and KO mice. After CsA treatment
eliminated by overnight fasting. The exact mechanismsfor seven days, the renal mRNA levels of both calcium
channels were not different from the pretreatment lev- of diet-dependent hypercalciuria in KO mice are not
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Fig. 2. Western blot analysis of the effect of cyclosporine A (CsA) on
calbindin D-28k expression in wild-type (WT) mice. Lane 1, untreated;
lane 3, CsA-treated; lane 4, 7 days after CsA withdrawal. Calbindin-
D28k was not detectable in the kidney of knockout (KO) mice (lane
3). The bar graph beneath shows that CsA treatment for 7 days resulted
in a 52% reduction in calbindin-D28k protein level (48  6 vs. 100 Fig. 1. RT-PCR analysis of the effect of cyclosporine A (CsA) on the
7%, *P  0.01 vs. untreated WT, N 	 4 in each group). This effectlevel of calbindin-D28k mRNA expressed in the kidney of wild-type
was completely reversed one week after discontinuing CsA (102  9%,(WT) mice. Lane 1, untreated; lane 3, CsA-treated. The cDNA product
P 
 0.05 vs. untreated WT).for calbindin-D28k is shown in the upper panel and-actin, which serves
as a control, in the lower panel. Calbindin-D28k was not detectable in
the kidney of knockout (KO) mice (lane 2). The bar graph beneath
shows that the relative calbindin-D28k/-actin ratio was significantly
to be the pathogenetic mechanism for CsA-induced hyp-reduced in CsA treated wild type mice (39  4% vs. 100  2%, *P 
0.01 vs. untreated WT. N 	 4 in each group). ercalciuria in rats [7, 15, 16]. It has been shown that the
total kidney calbindin-D28k mRNA and protein levels
decrease and calbindin-D28k immunohistochemical stain-
clear. It is possible that there is a compensatory increase ing in the DCT is reduced after CsA treatment [7]. Our
in intestinal calcium absorption, although the intestinal studies demonstrate that CsA has the same effect in
calbindin-D9k mRNA and protein levels are not in- mice, and that both hypercalciuria and down-regulation
creased in KO mice [23]. Alternatively, KO mice may of calbindin-D28k induced by CsA are reversible.
have a calcium transport defect in the distal tubule, which In our studies, CsA treatment resulted in a similar
only manifests when the ultrafiltered calcium load is ele- degree of hypercalciuria in both WT and KO mice, de-
vated by high calcium intake. Further studies are needed spite different pretreatment levels. The CsA-induced
to explore the mechanism of hypercalciuria in KO mice. hypercalciuria is unlikely due to tubular injury since the
As for bone turnover, calbindin-D28k is normally ex- serum creatinine level was unchanged, and there were
pressed in osteoblast cells and plays an important role no apparent histological changes on the renal tissue (data
in mineralized matrix formation in the bone [24, 25]. not shown). It is well established that CsA treatment
Our study results demonstrated, for the first time to our induces osteopenia and bone loss by accelerating bone
knowledge, that the plasma osteocalcin level was signifi- remodeling [18, 19]. Clinically, osteoporosis and in-
cantly lower in KO mice compared with the WT control. creased bone turnover have been reported in transplant
It is possible that KO mice may have decreased osteo- patients receiving CsA treatment [26, 27] and can be pre-
blastic activity, bone mineralization, and bone turnover. vented by bisphosphonates [28]. In animal studies, os-
Cyclosporine A therapy causes renal calcium wasting teopenia can develop rapidly within one week after CsA
in a dose- and time-dependent manner [5, 6]. Down- treatment in rats using a comparable dosage to that in
the present study [18, 29]. The enhanced bone turnoverregulation of renal calbindin-D28k has been proposed
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Fig. 3. Cyclosporine A (CsA) does not affect the level of epithelial calcium channel (ECaC) (A), and 1G subunit of voltage-gated calcium
channel (1G) (B) mRNA expressed in the kidney of wild-type (WT) and calbindin-D28k knockout (KO) mice. Quantitative RT-PCR analysis
was performed as described in the Methods section. Lane 1, untreated WT; lane 2, CsA-treated WT; lane 3, untreated KO; lane 4, CsA-treated
KO mice. N 	 4 in each group.
is closely related to the serum osteocalcin levels, which transported through the apical membrane by ECaC and
1G, binds to calbindin-D28k and calbindin-D9k, andincreased with CsA treatment and returned to the base-
line after withdrawal of CsA [30]. In our study, the serum exits through the basolateral membrane via the Na,
Ca2 exchanger and Ca2 pump [33]. The present studyosteocalcin levels in both WT and KO mice increased
by 50% after one week of CsA treatment. The elevation showed that CsA did not affect the abundance of ECaC
and 1G mRNA in the kidney. However, the possibilityof osteocalcin levels can be prevented by co-adminis-
tration of bisphosphonate, which inhibits bone resorp- of post-transcriptional or post-translational effects of
CsA on those channels was not ruled out in this study.tion. Similar results have been reported previously in
rat studies [20, 31]. Furthermore, with bisphosphonate If CsA only affects the transcellular transport of calcium
in the distal tubule via down-regulation of calbindin-treatment, the urinary Ca/Cr ratio reduced significantly
in both WT and KO mice. Since bisphosphonates do not D28k, we expect that after diminishing bone effects by
bisphosphonates, CsA treatment in KO mice would nothave any effects on renal calcium handling as shown
previously [32] as well as in the present study, the reduc- cause more urinary calcium leak. However, as shown in
Table 3, urine Ca/Cr was still significantly higher in KOtion of urinary calcium excretion is mainly due to inhibi-
tion of bone resorption. Therefore, our results indicate mice treated with CsA and APD when compared with
pretreatment levels. This increase was demonstratedthat increased bone resorption by CsA plays an impor-
tant role in the pathogenesis of hypercalciuria in both with or without overnight fasting. These results indicate
that the increase of renal calcium excretion by CsA inWT and KO mice.
It is certain that CsA treatment is associated with KO mice is due to mechanism(s) independent of calbin-
din-D28k. One potential mechanism is that CsA-induceddecreased renal calcium reabsorption because hypercal-
ciuria persists even when intestinal calcium absorption renal tubular acidosis [4] may enhance hypercalciuria,
as pH is an important regulator of distal calcium re-and bone resorption is limited by fasting and bisphospho-
nate treatment, respectively. In the kidney, calbindin- absorption [34].
We conclude that calbindin-D28k plays an importantD28k is only expressed in the distal tubule where calcium
reabsorption is highly regulated. Calcium is actively role in renal calcium reabsorption and bone metabolism.
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dependent calcium binding proteins increase calcium reabsorptionCalbindin-D28k KO mice have diet-dependent hypercal-
by different mechanisms. I. Effect of CaBP 28k. Kidney Int 45:461–
ciuria and a low plasma osteocalcin level, suggesting a 468, 1994
low bone turnover rate. CsA treatment induces hypercal- 12. Hoenderop JGJ, van der Kemp AW, Hartog A, et al: Molecular
identification of the apical Ca2 channel in 1,25 dihydroxyvitaminciuria by enhancing bone turnover and renal calcium
D3-responsive epithelia. J Biol Chen 274:8375–8378, 1999excretion. Bisphosphonate reverses CsA-associated high 13. Peng JB, Chen XZ, Berger UV, et al: A rat kidney-specific cal-
bone turnover and reduces the magnitude of renal cal- cium transporter in the distal nephron. J Biol Chem 275:28186–
28194, 2000cium wasting. Down-regulation of renal calbindin-D28k
14. Andreasen D, Jensen BL, Hansen PB, et al: The 1G-subunitcontributes at least in part to the pathogenesis of CsA- of a voltage-dependent Ca2 channel is localized in rat distal neph-
induced hypercalciuria, but there appear to be mecha- ron and collecting duct. Am J Physiol 279:F997–F1005, 2000
15. Steiner S, Aicher L, Raymackers J, et al: Cyclosporine A de-nisms independent of calbindin-D28k responsible for
creases the protein level of the calcium-binding protein calbindin-further renal calcium wasting. Currently, CsA and other D28kDa in rat kidney. Biochem Pharmacol 51:253–258, 1996
calcineurin inhibitors, such as FK506, are used widely 16. Grenet O, Varela MC, Staedtler F, Steiner S: The cyclosporine
A-induced decrease in rat renal calbindin-D28kDa protein as anot only for transplant patients, but also for patients
consequence of a decrease in its mRNA. Biochem Pharmacol 55:with a variety of autoimmune diseases. Our findings have
1131–1133, 1998
important clinical implications on the management of 17. Airaksinen MS, Eilers J, Garaschuk O, et al: Ataxia and altered
dendritic calcium signaling in mice carrying a targeted null muta-patients who receive calcineurin inhibitors.
tion of the calbindin D28k gene. Proc Natl Acad Sci USA 94:1488–
1493, 1997
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